<DOC>
	<DOCNO>NCT01705249</DOCNO>
	<brief_summary>This study conduct Europe . The aim study investigate bleed profile switch Trisekvens速 Activelle速 ( 1.0 mg estradiol / 0.5 mg norethisterone acetate ( NETA ) ) .</brief_summary>
	<brief_title>Bleeding Profile With Continuous Hormone Replacement Therapy Activelle速 Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Healthy woman At least 3 month Trisekvens速 screen period Ability understand comply protocol requirement Less 12 month 36 month postmenopausal judge Investigator Known , suspect , past history hormone dependent tumor/cancers Deep venous thrombosis , active thrombophlebitis , thromboembolic disorder , cerebrovascular accident past history condition Ischemic heart disease myocardial infarction within 6 month prior randomization</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>